Medigene Stock Forecast for 2023 - 2025 - 2030

Updated on 05/05/2024

Stock Rating
6
Price Target
2.68€
Consensus
Outperform
Upside
72.90%
Analysts
0
Stock Rating
6
Upside
72.90%
Analysts
0
Price Target
2.68€

Medigene Stock Forecast and Price Target

If the average 2024 price target of 2.68€ recently set by prominent experts for Medigene is met, there would be a potential upside of approximately 72.9% from the last closing price in May, 2024. The high estimate is 3.00€, and the low is 2.35€. Even if you are not interested in MDG1 stock, you should be aware of its competitors and their current standings.

2.68€

72.90% Upside

Buy
Buy

Medigene Fair Value Forecast for 2023 - 2025 - 2030

In the last three years, Medigene's Price has seen an increase, rising from 0.00€ to 0.00€. This represents a growth of 100.00%. Analysts predict that Medigene's Fair Value will increase in the upcoming year, reaching 1.63€. This would represent an increase of 100.00%. Over the next seven years, experts predict that Medigene's Fair Value will grow at a rate of 100.00%.

2024 Fair Value Forecast
1.63€
2025 Fair Value Forecast
1.75€
2026 Fair Value Forecast
1.89€
2027 Fair Value Forecast
2.04€
2028 Fair Value Forecast
2.20€
2029 Fair Value Forecast
2.37€
2030 Fair Value Forecast
2.55€

Medigene Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Medigene's Revenue has seen an increase, rising from 8.00€M to 31.25€M. This represents a growth of 290.63%. In the following year, 2 experts forecast Medigene's Revenue will decrease by 63.20%, to 11.50€M. In 2030, professionals predict that Medigene's Revenue will decrease by 24.48%, to 23.60€M.

2024 Rev Forecast
0.01€B
2025 Rev Forecast
0.01€B
2026 Rev Forecast
0.02€B
2027 Rev Forecast
0.02€B
2028 Rev Forecast
0.02€B
2029 Rev Forecast
0.02€B
2030 Rev Forecast
0.02€B

Medigene Dividend per Share Forecast for 2023 - 2025 - 2030

Medigene Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
-11500000.00€
2025 FCF Forecast
-18100000.00€
2026 FCF Forecast
-11500740.00€
2027 FCF Forecast
-14502433.14€
2028 FCF Forecast
-14513068.26€
2029 FCF Forecast
-16284146.35€
2030 FCF Forecast
-14566168.91€

Medigene EBITDA Forecast for 2023 - 2025 - 2030

Medigene's EBITDA has grown in the last two years, jumping from -23.82€M to 32.77€M – an increase of 237.57%. According to 2 analysts, Medigene's EBITDA will fall by 133.38% in the next year, reaching -10.94€M. Professionals believe that By 2030, Medigene's EBITDA will fall to -26.73€M – a 181.57% decrease from its current value.

2024 EBITDA Forecast
-10940000.00€
2025 EBITDA Forecast
-16990000.00€
2026 EBITDA Forecast
-14710000.00€
2027 EBITDA Forecast
-15180000.00€
2028 EBITDA Forecast
-23370000.00€
2029 EBITDA Forecast
-24860000.00€
2030 EBITDA Forecast
-26730000.00€

Medigene EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Medigene's EBIT has increased by 142.94%, going from -27.20€M to 11.68€M. In the following year, 2 experts forecast that Medigene's EBIT will decrease by 201.46%, to -11.85€M. In 2030, professionals predict that Medigene's EBIT will decrease by 345.72%, to -28.70€M.

2024 EBIT Forecast
-11850000.00€
2025 EBIT Forecast
-17950000.00€
2026 EBIT Forecast
-15800000.00€
2027 EBIT Forecast
-16300000.00€
2028 EBIT Forecast
-25100000.00€
2029 EBIT Forecast
-26700000.00€
2030 EBIT Forecast
-28700000.00€

Medigene EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last three years, Medigene's EPS has seen an increase, rising from -1.18€ to 0.00€. This represents a growth of 100.00%. Analysts predict that Medigene's EPS will increase in the upcoming year, reaching -0.40€. This would represent an increase of 100.00%. Over the next seven years, experts predict that Medigene's EPS will grow at a rate of 100.00%.

2024 EPS Forecast
-0.40€
2025 EPS Forecast
-0.59€
2026 EPS Forecast
-0.35€
2027 EPS Forecast
-0.28€
2028 EPS Forecast
-0.42€
2029 EPS Forecast
-0.44€
2030 EPS Forecast
-0.44€